AstraZeneca India ko mili CDSCO approval! Gastric Cancer ka naya ilaaj Imfinzi ab India mein allowed

HEALTHCAREBIOTECH

Overview

AstraZeneca Pharma India ke liye ye ek badi khabar hai! Company ko CDSCO (Central Drugs Standard Control Organisation) se crucial approval mil gayi hai apne drug Durvalumab (Imfinzi) ke liye. Ab ye drug adults mein gastric cancer ya gastroesophageal junction adenocarcinoma ke liye bhi use ho sakta hai, woh bhi FLOT chemotherapy ke saath combine karke.

Ye approval kyun hai itni khaas?

Aise dekho, AstraZeneca ne India mein apne oncology portfolio ko aur mazboot kar liya hai. Imfinzi ab sirf pehle wali indication ke liye nahi, balki gastric cancer ke liye bhi approved hai. Ye approval un patients ke liye hai jinko resectable gastric ya gastroesophageal junction adenocarcinoma hai. Treatment mein Imfinzi ko FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, aur docetaxel) ke saath pre-surgery (neoadjuvant) aur post-surgery (adjuvant) dono tarah se diya jaayega. Uske baad single-agent Durvalumab therapy bhi hogi.

Isse company ka aim hai India mein un medical needs ko poora karna jahan abhi ilaaj ki zaroorat zyada hai. Isse company ki oncology segment mein pakad aur mazboot hogi aur revenue bhi badhne ki ummeed hai.

Aage kya?

CDSCO ki approval mil gayi hai, par abhi bhi kuch aur statutory approvals chahiye hongi taaki isse market mein launch kiya jaa sake. Investors ab dekhenge ki doctor log is drug ko kitna accept karte hain, iska price kya hoga, aur ye Indian patients par kitna effective aur safe prove hota hai. Yeh ek achha opportunity hai AstraZeneca ke liye growth ka.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.